Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Resmed (RSMDF) over the last 16 years, with Q4 2025 value amounting to $391.5 million.

  • Resmed's Accumulated Expenses rose 1105.09% to $391.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $391.5 million, marking a year-over-year increase of 1105.09%. This contributed to the annual value of $402.3 million for FY2025, which is 650.69% up from last year.
  • Per Resmed's latest filing, its Accumulated Expenses stood at $391.5 million for Q4 2025, which was up 1105.09% from $395.8 million recorded in Q3 2025.
  • In the past 5 years, Resmed's Accumulated Expenses ranged from a high of $402.3 million in Q2 2025 and a low of $274.1 million during Q3 2021
  • Over the past 5 years, Resmed's median Accumulated Expenses value was $347.8 million (recorded in 2023), while the average stood at $345.7 million.
  • Within the past 5 years, the most significant YoY rise in Resmed's Accumulated Expenses was 2954.58% (2021), while the steepest drop was 157.38% (2021).
  • Over the past 5 years, Resmed's Accumulated Expenses (Quarter) stood at $286.8 million in 2021, then increased by 8.84% to $312.2 million in 2022, then rose by 6.4% to $332.1 million in 2023, then rose by 6.14% to $352.5 million in 2024, then increased by 11.05% to $391.5 million in 2025.
  • Its Accumulated Expenses stands at $391.5 million for Q4 2025, versus $395.8 million for Q3 2025 and $402.3 million for Q2 2025.